Keya Joshi
YOU?
Author Swipe
View article: The Potential Public Health Impact of the mRNA-Based Respiratory Syncytial Virus Vaccine, mRNA-1345, Under Extended Vaccination Campaigns Among Older Adults in the United Kingdom: A Modelling Study
The Potential Public Health Impact of the mRNA-Based Respiratory Syncytial Virus Vaccine, mRNA-1345, Under Extended Vaccination Campaigns Among Older Adults in the United Kingdom: A Modelling Study Open
Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease in older adults. Despite growing recognition of RSV as a public health concern, vaccination options remain limited. This study assess…
View article: Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact Assessment
Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact Assessment Open
Aims COVID-19 disease burden in United States (US) older adults ≥65 years and persons with underlying medical conditions remains high. This modeling study provides an interim estimate of the anticipated public health impact of the next-gen…
View article: The Potential Public Health Impact of the mRNA-based Respiratory Syncytial Virus Vaccine, mRNA-1345, Under Extended Vaccination Campaigns Among Older Adults in the United Kingdom: A Modelling Study
The Potential Public Health Impact of the mRNA-based Respiratory Syncytial Virus Vaccine, mRNA-1345, Under Extended Vaccination Campaigns Among Older Adults in the United Kingdom: A Modelling Study Open
Background/Objectives Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease in older adults. Despite growing recognition of RSV as a public health concern, vaccination options remain limited. This study assesse…
View article: The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada
The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada Open
mRNA-1283 could reduce the COVID-19 clinical burden and provide economic value for the NACI-recommended population, exceeding current mRNA vaccines; COVID-19 program planners may consider supporting access to mRNA-1283 to optimize public h…
View article: Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value
Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value Open
Background The clinical and economic burden of respiratory syncytial virus (RSV) is significant; millions of patients seek medical care due to RSV infections each year. Recently approved vaccines offer an important opportunity to reduce th…
View article: The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in Canada
The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in Canada Open
Background With continued high disease burden observed in vulnerable groups and fiscal responsibility shifting to Canada’s jurisdictions, assessing the economic value of COVID-19 vaccines is critical for optimizing COVID-19 prevention. Thi…
View article: Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees
Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees Open
The objectives were to assess the economic burden of COVID-19 and impact of workplace COVID-19 vaccination in the United States (US). An economic model estimated COVID-19 workplace burden (infections, long COVID, inpatient/outpatient care,…
View article: Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era
Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era Open
Background/Objectives: COVID-19 continues to challenge public health due to emerging variants. To mitigate this, the Korea Disease Control and Prevention Agency (KDCA) recommends annual COVID-19 vaccination, but uptake remains suboptimal. …
View article: Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged ≥ 18 years in the United States
Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged ≥ 18 years in the United States Open
Background This study evaluated the effectiveness of Moderna’s updated mRNA-1273 vaccine targeting the KP.2 variant, compared to people who did not receive any 2024-2025 COVID-19 vaccine, in preventing COVID-19-associated hospitalizations …
View article: Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID-19 Conditions: Findings from a Literature Review
Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID-19 Conditions: Findings from a Literature Review Open
Approximately 10–20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs associated with LC. Be…
View article: Cryo-EM reveals a new allosteric binding site at the M<sub>5</sub>mAChR
Cryo-EM reveals a new allosteric binding site at the M<sub>5</sub>mAChR Open
The M 5 muscarinic acetylcholine receptor (M 5 mAChR) represents a promising therapeutic target for neurological disorders. However, the high conservation of its orthosteric binding site has posed significant challenges for drug developmen…
View article: The potential clinical impact and cost-effectiveness of a variant-adapted 2024 Winter and Summer COVID-19 mRNA vaccination campaign in Australia
The potential clinical impact and cost-effectiveness of a variant-adapted 2024 Winter and Summer COVID-19 mRNA vaccination campaign in Australia Open
Objectives To assess the clinical and economic impact, and cost-effectiveness, of a 2024 Winter and Summer COVID-19 Vaccination Campaign (2024 Vaccination Campaign) in Australia compared to no 2024 Vaccination Campaign. Design Modelling st…
View article: Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France Open
An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in Fall …
View article: Activation of polycystin-1 signaling by binding of stalk-derived peptide agonists
Activation of polycystin-1 signaling by binding of stalk-derived peptide agonists Open
Polycystin-1 (PC1) is the protein product of the PKD1 gene whose mutation causes autosomal dominant Polycystic Kidney Disease (ADPKD). PC1 is an atypical G protein-coupled receptor (GPCR) with an autocatalytic GAIN domain that cleaves PC1 …
View article: The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom Open
Vaccination of the eligible population would contribute to significant reductions in hospitalizations, deaths, and long COVID in the UK in the 2024-2025 season. Expanding the target population continues to be cost-effective. Use of the Mod…
View article: Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434”
Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434” Open
In their comment [...]
View article: Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID Conditions: Findings from a Literature Review
Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID Conditions: Findings from a Literature Review Open
Approximately 10–20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs associated with LC. Be…
View article: The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom Open
Aims To estimate the potential clinical impact and cost-effectiveness of a United Kingdom (UK) Autumn 2024 vaccination campaign with an updated Moderna COVID-19 vaccine in adults ≥65 years and eligible persons 6 months to 64 years of age o…
View article: Activation of Polycystin-1 Signaling by Binding of Stalk-derived Peptide Agonists
Activation of Polycystin-1 Signaling by Binding of Stalk-derived Peptide Agonists Open
Polycystin-1 (PC1) is the membrane protein product of the PKD1 gene whose mutation is responsible for 85% of the cases of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is primarily characterized by the formation of renal cyst…
View article: Workplace Vaccination against COVID-19 and Seasonal Influenza in the United States: A Modeling Based Estimation of the Health and Economic Benefits for Employers and Employees
Workplace Vaccination against COVID-19 and Seasonal Influenza in the United States: A Modeling Based Estimation of the Health and Economic Benefits for Employers and Employees Open
Background: COVID-19 has a major impact on businesses, with employee absenteeism resulting in lost productivity and medical costs to employers as well as lost wages and medical costs to employees. The aim of this analysis was to assess the…
View article: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan Open
This analysis estimates the economic and clinical impact of a Moderna updated COVID-19 mRNA Fall 2023 vaccine for adults ≥18 years in Japan. A previously developed Susceptible-Exposed-Infected-Recovered (SEIR) model with a one-year analyti…
View article: Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France Open
An economic evaluation was conducted to predict the economic and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 and Spring 2024 versus BNT162b2…
View article: Gaussian Accelerated Molecular Dynamics in Drug Discovery
Gaussian Accelerated Molecular Dynamics in Drug Discovery Open
This chapter summarizes recent methodological developments and application studies of Gaussian accelerated molecular dynamics (GaMD) in drug discovery. GaMD is an unconstrained enhanced sampling technique that allows for exploration of the…
View article: Activation of Polycystin-1 Signaling by Binding of Stalk-derived Peptide Agonists
Activation of Polycystin-1 Signaling by Binding of Stalk-derived Peptide Agonists Open
Polycystin-1 (PC1) is the membrane protein product of the PKD1 gene whose mutation is responsible for 85% of the cases of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is primarily characterized by the formation of renal cyst…
View article: Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany Open
The mRNA-1273.815 vaccine can be considered cost-effective relative to the XBB.1.5 BNT162b2 vaccine and highly likely to provide more benefits and save costs compared to no vaccine in Germany, and to offer high societal return on investmen…
View article: 1635. Assessing the Potential Reduction in Morbidity and Mortality Attainable by Delayed Influenza Vaccine Strain Selection
1635. Assessing the Potential Reduction in Morbidity and Mortality Attainable by Delayed Influenza Vaccine Strain Selection Open
Background To allow time for production, seasonal influenza vaccine target strains must be chosen up to 8 months before the start of the influenza season. Antigenic drift during these months can lead to mismatch between the circulating and…